<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621538</url>
  </required_header>
  <id_info>
    <org_study_id>22145</org_study_id>
    <secondary_id>R00AA027830</secondary_id>
    <nct_id>NCT05621538</nct_id>
  </id_info>
  <brief_title>A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder</brief_title>
  <acronym>CNT</acronym>
  <official_title>A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auburn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Auburn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical study is to test the effectiveness of a supplemental fMRI&#xD;
      neurofeedback and/or TMS intervention in individuals seeking treatment for Alcohol Use&#xD;
      Disorder.&#xD;
&#xD;
      After an initial visit, participants will come in once a week for four (4) weeks for an&#xD;
      intervention session, which may or may not include TMS and MRI. Participants will be&#xD;
      contacted for monthly follow-ups (remotely) for up to 12 months and will be asked to come in&#xD;
      for two MRI follow-ups at 6 and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2023</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The PI will prospectively assign treatment groups with blind codes and so will not be blind to treatment type. Other staff, who are the individuals primarily working with the patients and who will be conducting follow-up interviews, will be blind to treatment type. It is not possible to blind the 5th condition (treatment as usual with a brief check-in).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Alcohol Use over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 2-5 (intervention sessions, pre and post), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)</time_frame>
    <description>Alcohol Timeline Followback (alc-TLFB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Alcohol Craving over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 2-5 (intervention sessions, pre and post), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)</time_frame>
    <description>Alcohol Craving Questionnaire (ACQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Community Functioning over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)</time_frame>
    <description>Drinker Inventory of Consequences (DrInC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Employment Status over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 33, 37, 41, 45, 49, 53 (follow-ups)</time_frame>
    <description>self-reported employment status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Aggression and Victimization over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57 (follow-ups)</time_frame>
    <description>Revised Conflict Tactics Scales (CTS-R)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Antisocial Behavior over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 2-5 (intervention sessions), 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57 (follow-ups)</time_frame>
    <description>number of self-reported contacts with the police, convictions, and other criminal behaviors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Brain Activity during Alcohol Cue Presentation over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)</time_frame>
    <description>Measured via fMRI; standard alcohol cue reactivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Brain Activity during Simultaneous Sociomoral &amp; Alcohol Cue Presentation over Time</measure>
    <time_frame>Assessed at weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)</time_frame>
    <description>Measured via fMRI; alcohol-cued sociomoral processing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Gray Matter Structure over Time</measure>
    <time_frame>Weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)</time_frame>
    <description>Measured via MRI; gray matter volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain White Matter Structure over Time</measure>
    <time_frame>Weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)</time_frame>
    <description>Measured via MRI; white matter diffusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Resting State Functional Connectivity over Time</measure>
    <time_frame>Weeks: 1 (baseline), 5 (post final intervention), 29 and 57 (follow-ups)</time_frame>
    <description>Measured via fMRI</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Neurofeedback-active + TMS-active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurofeedback-active + TMS-sham</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of own brain activity from multiple ROIs measured using fMRI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurofeedback-sham + TMS-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 sessions of: TMS (protocol: 10 Hz pulses delivered at 110% of MT in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurofeedback-sham + TMS-sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>4 sessions of: TMS (protocol: 10 Hz pulses delivered using the Sham TMS coil in 60 x 5 sec trains with 25 sec ITI) Neurofeedback (protocol: presentation of other's brain activity from multiple ROIs measured using fMRI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Check-In Only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>4 sessions of: Completing typical pre-TMS/MRI procedures Being prompted to reflect on outside treatment (TAU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Realtime fMRI Neurofeedback - Active</intervention_name>
    <description>fMRI aided reinforcement of craving regulation</description>
    <arm_group_label>Neurofeedback-active + TMS-active</arm_group_label>
    <arm_group_label>Neurofeedback-active + TMS-sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS - Active</intervention_name>
    <description>rTMS to right dorsolateral prefrontal cortex to reduce craving</description>
    <arm_group_label>Neurofeedback-active + TMS-active</arm_group_label>
    <arm_group_label>Neurofeedback-sham + TMS-active</arm_group_label>
    <other_name>Magventure Magpro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Realtime fMRI Neurofeedback - Yoked Sham</intervention_name>
    <description>Display of feedback from other participant's sessions to serve as a sham for fMRI aided reinforcement of craving regulation</description>
    <arm_group_label>Neurofeedback-sham + TMS-active</arm_group_label>
    <arm_group_label>Neurofeedback-sham + TMS-sham</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TMS - Sham</intervention_name>
    <description>rTMS using placebo coil (no brain stimulation, emulates other features of active TMS), placed over right dorsolateral prefrontal cortex</description>
    <arm_group_label>Neurofeedback-active + TMS-sham</arm_group_label>
    <arm_group_label>Neurofeedback-sham + TMS-sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19-65&#xD;
&#xD;
          2. Receiving treatment for Alcohol Use Disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MRI Contraindications&#xD;
&#xD;
               1. Presence of metal in the body that would make having a 7T MRI unsafe (including&#xD;
                  facial tattoos)&#xD;
&#xD;
               2. Claustrophobia, such that individual would be unable to stay in the MRI for up to&#xD;
                  1 hr&#xD;
&#xD;
               3. Hearing loss, including tinnitus, that might be made worse by MRI or TMS&#xD;
&#xD;
          2. TMS Contraindications&#xD;
&#xD;
               1. Has ever had a seizure, or has a family history of epilepsy&#xD;
&#xD;
               2. Taking medications or substances that lower the seizure threshold&#xD;
&#xD;
               3. Implanted devices that are in the head or rely on physiological signals&#xD;
&#xD;
               4. History of neurological disease, such as stroke or brain tumor&#xD;
&#xD;
               5. Head injury with loss of consciousness greater than 30 minutes&#xD;
&#xD;
               6. Actively withdrawing from alcohol&#xD;
&#xD;
          3. Family history of schizophrenia or presence of psychotic symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samantha J Fede, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auburn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SCAMPI Lab</last_name>
    <phone>334-521-2807</phone>
    <email>scampi@auburn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auburn University</name>
      <address>
        <city>Auburn</city>
        <state>Alabama</state>
        <zip>36849</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>SCAMPI Lab</last_name>
      <phone>334-521-2807</phone>
      <email>scampi@auburn.edu</email>
    </contact>
    <investigator>
      <last_name>Samantha J Fede, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Auburn University</investigator_affiliation>
    <investigator_full_name>Samantha Fede</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>treatment seeking</keyword>
  <keyword>alcohol</keyword>
  <keyword>TMS</keyword>
  <keyword>neurofeedback</keyword>
  <keyword>supplemental intervention</keyword>
  <keyword>heavy drinking</keyword>
  <keyword>problems with drinking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared within the NIAAA Data Archive according to the standard data sharing plan. Deidentified individual data regarding the outcome variables (clinical and MRI) will be included. Participants will have the option to opt out of sharing their individual data.&#xD;
Given the highly sensitive and confidential nature of the information, and the magnitude of potential harms to participants associated with disclosure, clinical outcome data pertaining to criminal acts and illegal activities will not be available in the data repository.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

